Frequently Asked Questions
North America dominates the amyotrophic lateral sclerosis (ALS) market due to the presence of major key players, favorable reimbursement policies and well-developed healthcare infrastructure in this region.
Type, treatment type, diagnosis, symptoms, end-users, and distribution channel are the factors on which the amyotrophic lateral sclerosis (ALS) market research is based.
The rise in the prevalence of amyotrophic lateral sclerosis & rising healthcare expenditure are the growth drivers of the amyotrophic lateral sclerosis (ALS) market.
The growth rate of the amyotrophic lateral sclerosis (ALS) market is 6.13% by 2029.
Major companies in the amyotrophic lateral sclerosis (ALS) market are in the amyotrophic lateral sclerosis (ALS) market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi, Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, and ADVANZ PHARMA, among others.
